Safety Evaluation of Intravenous Talineuren (TLN) in Parkinson's Disease-affected Patients
Status:
Not yet recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
This study is an open-label, single ascending dose escalation followed by a multiple
administration dose at the maximal suitable dose (MSD). The investigational Medicinal Product
(IMP) is given as an add-on therapy.
Talineuren consists of GM1 (monosialotetrahexosylganglioside), the pharmacologically active
ingredient, associated with a proprietary lipid formulation assembled as liposomes.
The primary objective is to demonstrate the safety of TLN administration intravenously in
Parkinson patients.
Secondary objectives are the determination of the maximal suitable dose based on the safety
profile and preliminary efficacy, as well as the determination of the pharmacokinetics (PK)
profile.